<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9842">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05689047</url>
  </required_header>
  <id_info>
    <org_study_id>MS201618_0033</org_study_id>
    <nct_id>NCT05689047</nct_id>
  </id_info>
  <brief_title>Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)</brief_title>
  <official_title>Phase IIa Proof of Concept, Multicenter, Randomized, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Combination M5717 Plus Pyronaridine Administered Once Daily for 1 or 2 Days to Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetic of the&#xD;
      combination M5717 plus pyronaridine in participants with acute uncomplicated Plasmodium&#xD;
      falciparum malaria. Pyramax (Artesunate/Pyronaridine) will act as an internal control&#xD;
      providing reference safety data and a benchmark for the efficacy evaluation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2023</start_date>
  <completion_date type="Anticipated">November 24, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 24, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Related TEAEs</measure>
    <time_frame>Day 1 up to Day 43</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of Participants With Clinically Significant Change From Baseline in Safety Laboratory Parameters, Vital Signs and 12-lead Electrocardiogram (ECG) Findings</measure>
    <time_frame>Day 1 up to Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Percentage of Participants with Polymerase Chain Reaction (PCR)-Adjusted Adequate Clinical and Parasitological Response (ACPR)</measure>
    <time_frame>At Day 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Pharmacokinetic Plasma Concentration of M5717 and Pyronaridine</measure>
    <time_frame>Day 1 up to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Percentage of Participants with Early Treatment Failure (ETF)</measure>
    <time_frame>Day 1,2 and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Percentage of Participants with Late Clinical Failure (LCF)</measure>
    <time_frame>From Day 5 to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Percentage of Participants with Late parasitological failure (LPF)</measure>
    <time_frame>From Day 8 to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Percentage of Participants With Crude Adequate Clinical and Parasitological Response (ACPR)</measure>
    <time_frame>Day 15, 29 and 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Percentage of Participants with Polymerase Chain Reaction (PCR)-Adjusted Adequate Clinical and Parasitological Response (ACPR)</measure>
    <time_frame>Day 15, 29 and 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Percentage of Participants with Polymerase Chain Reaction (PCR)-Adjusted Adequate Clinical and Parasitological Response (ACPR)</measure>
    <time_frame>At Day 15 and 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Percentage of Participants with Crude (PCR-uncorrected) Efficacy</measure>
    <time_frame>At Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Percentage of Participants with PCR-Adjusted Efficacy</measure>
    <time_frame>At Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Parasite Reduction Rate</measure>
    <time_frame>Upto 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Time to Fever Clearance as Estimated by Kaplan-Meier Method</measure>
    <time_frame>Day 1 up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Parasite Clearance Time as Estimated by Kaplan-Meier Method</measure>
    <time_frame>Day 1 up to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Time to Recrudescence as Estimated by Kaplan-Meier Method</measure>
    <time_frame>Day 1 up to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Time to Re-Infection as Estimated by Kaplan-Meier Method</measure>
    <time_frame>Up to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Time to Re-Emergence as Estimated by Kaplan-Meier Method</measure>
    <time_frame>Up to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Related TEAEs</measure>
    <time_frame>Up to Day 43</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">137</enrollment>
  <condition>Acute Malaria</condition>
  <arm_group>
    <arm_group_label>Part A: Safety Run-in Cohort M5717+Pyronaridine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>M5717 and pyronaridine once daily in a single day treatment regimen at low dose of 330 milligrams (mg) and 360 mg respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Dose escalation cohort; M5717+Pyronaridine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After completion of Part A, if dose will be considered safe and well tolerated, the Internal Data Monitoring Committee (IDMC) will have the option to recommend dose adjustments. M5717 and pyronaridine once daily will be administered in an escalated dose in a single day or 2-day treatment regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pyronaridine-artesunate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pyronaridine-artesunate (Pyramax) once daily in a 3-day treatment regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M5717 330 mg</intervention_name>
    <description>Participants will receive orally 330 mg granules of M5717 in combination with pyronaridine dispersed in water under fasting condition.</description>
    <arm_group_label>Part A: Safety Run-in Cohort M5717+Pyronaridine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M5717 500 mg</intervention_name>
    <description>Adolescent participants with weight less than (&lt;) 45 kilograms (kg) will receive orally 500 mg granules of M5717 in combination with pyronaridine dispersed in water once daily under fasting condition.</description>
    <arm_group_label>Part B: Dose escalation cohort; M5717+Pyronaridine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M5717 660 mg</intervention_name>
    <description>Adult and adolescent participants with weight more than or equal to (&gt;=) 45 kg will receive orally 660 mg granules of M5717 in combination with pyronaridine dispersed in water once daily under fasting condition.</description>
    <arm_group_label>Part B: Dose escalation cohort; M5717+Pyronaridine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyronaridine 360 mg</intervention_name>
    <description>Participants will receive 360 mg of pyronaridine tablets in combination with M5717 under fasting condition.</description>
    <arm_group_label>Part A: Safety Run-in Cohort M5717+Pyronaridine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyronaridine 360 mg</intervention_name>
    <description>Participants with weight &gt;=24 to &lt;45 kg will receive 360 mg of tablets in combination with M5717 under fasting condition.</description>
    <arm_group_label>Part B: Dose escalation cohort; M5717+Pyronaridine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyronaridine 540 mg</intervention_name>
    <description>Participants with weight &gt;=45 to &lt;65 kg will receive 540 mg of Pyronaridine tablets in combination with M5717 under fasting condition.</description>
    <arm_group_label>Part B: Dose escalation cohort; M5717+Pyronaridine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyronaridine 720 mg</intervention_name>
    <description>Participants with weight &gt;=65 kg will receive 720 mg of Pyronaridine tablets in combination with M5717 under fasting condition.</description>
    <arm_group_label>Part B: Dose escalation cohort; M5717+Pyronaridine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyronaridine-artesunate (Pyramax) 360 mg/120 mg</intervention_name>
    <description>Participants with weight &gt;=24 to &lt;45 kg will receive dose of 360/120 mg dose of Pyronaridine- artesunate (Pyramax) tablets under fasting condition.</description>
    <arm_group_label>Pyronaridine-artesunate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyronaridine- artesunate (Pyramax) 540 mg/180 mg</intervention_name>
    <description>Participants with weight &gt;=45 to &lt;65 kg will receive 540/180 mg dose of Pyronaridine-artesunate (Pyramax) tablets under fasting condition.</description>
    <arm_group_label>Pyronaridine-artesunate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyronaridine-artesunate (Pyramax) 720 mg/240 mg</intervention_name>
    <description>Participants with weight &gt;=65 kg will receive 720/240 mg dose of Pyronaridine- artesunate (Pyramax) tablets under fasting condition.</description>
    <arm_group_label>Pyronaridine-artesunate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants with microscopic confirmation of acute uncomplicated Plasmodium&#xD;
             falciparum using Giemsa-stained thick and thin film&#xD;
&#xD;
          -  P. falciparum parasitemia of 1,000 to 50,000 asexual parasites/microliter of blood in&#xD;
             Part A and P. falciparum parasitemia of &gt;1,000 to &lt;= 150,000 asexual&#xD;
             parasites/microliter of blood in Part B&#xD;
&#xD;
          -  Axillary temperature &gt;= 37.5 degree Celsius or tympanic temperature &gt;= 38.0 degree&#xD;
             Celsius (use as per Coronavirus disease 2019 (COVID-19) protocols at the site [only at&#xD;
             Screening]), or history of fever during the previous 24 hours (at least documented&#xD;
             verbally)&#xD;
&#xD;
          -  The Investigator confirms that each participant agrees to use appropriate&#xD;
             contraception and barriers, if applicable&#xD;
&#xD;
          -  Capable of giving signed informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the Informed Consent Form (ICF) and this&#xD;
             protocol&#xD;
&#xD;
          -  Other protocol defined inclusion criteria could apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mixed Plasmodium infections as per thin film microscopy results&#xD;
&#xD;
          -  Signs and symptoms of severe malaria according to World Health Organisation (WHO) 2021&#xD;
             criteria (WHO 2021)&#xD;
&#xD;
          -  Known liver abnormalities, liver cirrhosis (compensated or decompensated), known&#xD;
             active or history of hepatitis B or C (testing not required), underlying hepatic&#xD;
             injury or known severe liver disease, known gallbladder or bile duct disease, acute or&#xD;
             chronic pancreatitis, or severe malnutrition&#xD;
&#xD;
          -  Known history or evidence of clinically significant disorders such as, cardiovascular,&#xD;
             respiratory (including active tuberculosis), hepatic, renal, gastrointestinal,&#xD;
             immunological [including known Human Immunodeficiency Virus-Acquired Immunodeficiency&#xD;
             Syndrome (HIV-AIDS)], neurological (including auditory), endocrine, infectious,&#xD;
             malignancy, psychiatric, history of convulsions, or other abnormality (including head&#xD;
             trauma)&#xD;
&#xD;
          -  Previous treatment with pyronaridine as part of a combination therapy during the last&#xD;
             3 months&#xD;
&#xD;
          -  Prior antimalarial therapy or antibiotics with antimalarial activity within a minimum&#xD;
             of their 5 plasma half-lives (or within 4 weeks of Screening if half-life is unknown)&#xD;
&#xD;
          -  Participants taking medications prohibited by the protocol&#xD;
&#xD;
          -  Other protocol defined exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@emdgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut de Recherche en Sciences de la Santé (IRSS)</name>
      <address>
        <city>Nanoro</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+226 70675780</phone>
      <email>lingani10@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Moussa Lingani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe de Recherche Action en Santé (GRAS)</name>
      <address>
        <city>Ouagadougou</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+226 7028 5726</phone>
      <email>a.tiono@gras.bf</email>
    </contact>
    <investigator>
      <last_name>B.Alfred Tiono</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Recherches Médicales de Lambaréné (CERMEL)</name>
      <address>
        <city>Lambarene</city>
        <country>Gabon</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+241 7715 15748</phone>
      <email>manegorella@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Zoleko Manego Rella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Investigação em saúde de Manhiça/Fundação Manhiça (CISM/FM)</name>
      <address>
        <city>Maputo</city>
        <country>Mozambique</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>0034 932275400</phone>
      <phone_ext>4121</phone_ext>
      <email>Quique.bassat@isglobal.org</email>
    </contact>
    <investigator>
      <last_name>Quique Bassat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Research Collaboration (IDRC)</name>
      <address>
        <city>Tororo</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+256 7724 73533</phone>
      <email>yadoke@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Yeka Adoke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
    <country>Gabon</country>
    <country>Mozambique</country>
    <country>Uganda</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS201618_0033</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>January 9, 2023</study_first_submitted>
  <study_first_submitted_qc>January 9, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2023</study_first_posted>
  <last_update_submitted>May 4, 2023</last_update_submitted>
  <last_update_submitted_qc>May 4, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>M5717</keyword>
  <keyword>Plasmodium mutants</keyword>
  <keyword>Acute Malaria</keyword>
  <keyword>Pyronaridine</keyword>
  <keyword>Plasmodium falciparum</keyword>
  <keyword>Polymerase chain reaction</keyword>
  <keyword>Adequate Clinical and Parasitological Response</keyword>
  <keyword>Plasmodium eukaryotic translation Elongation Factor 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Pyronaridine</mesh_term>
    <mesh_term>Pyronaridine tetraphosphate, artesunate drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Within six months after the approval of a new product or a new indication for an approved product in both the United States and the European Union</ipd_time_frame>
    <ipd_access_criteria>Qualified scientific and medical researchers can request the data. Such requests must be submitted in writing to the company's portal and will be internally reviewed regarding criteria for researchers' qualification and legitimacy of the research proposal.</ipd_access_criteria>
    <ipd_url>https://bit.ly/IPD21</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

